Replies to post #54819 on Amarin Corp Plc (AMRN)

[Ray]

JL ....... I'll address this with you. If you read the PFE website (see attached link), you'll notice they are moving into the inflammatory market. However, their focus appears to be at the molecular level targeting disease with a "system" approach. I referenced a small stake in a Dutch company in my post dated 07/28. While EPA - and specifically Vascepa - doesn't address this field, I have to believe Vascepa would be a nice "bolt on" at some point in the near future. What's your opinion?

http://www.pfizer.com/partnering/areas_of_interest/inflammation_and_remodeling